期刊
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
卷 19, 期 11, 页码 1233-1239出版社
WILEY
DOI: 10.1111/j.1440-1746.2003.03325.x
关键词
chronic hepatitis; interferon; pegylated; ribavirin; therapy
Hepatitis C virus (HCV) genotype 4 is predominantly found in the Middle East and North Africa. Because most of the large randomized controlled trials of antiviral therapy for chronic hepatitis C were conducted in North America and Europe, little is known about management of patients with this particular genotype. Based on the available data, sustained virological response rates to interferon-based therapies appear to be intermediate between the relatively resistant HCV genotype I and the readily responsive genotypes 2 and 3. Several large prospective studies of pegylated interferon plus ribavirin combination therapy, the current gold-standard treatment, have recently been completed and will be reviewed. (C) 2004 Blackwell Publishing Asia Pry Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据